Themis pulls out of IPO, looks into 'strategic options' to fund phase 3 vaccine trial

Themis Bioscience has postponed its planned IPO in Amsterdam. The Austrian biotech is now looking into “all strategic options” to secure the cash it needs to move its chikungunya vaccine into phase 3.